Methotrexate Dosing for Disseminated Sarcoidosis
For disseminated sarcoidosis, start oral methotrexate at 10–15 mg once weekly and escalate by 5 mg every 2–4 weeks to a target of 20–25 mg/week, with monitoring of CBC, liver enzymes, and creatinine every 1–1.5 months until stable, then every 1–3 months thereafter. 1, 2
Initial Dosing Strategy
Begin with 10–15 mg oral methotrexate once weekly, as recommended by multinational rheumatology guidelines that specifically endorse methotrexate for sarcoidosis as a steroid-sparing agent. 1
The 2021 ERS clinical practice guidelines on sarcoidosis treatment list methotrexate as a standard immunosuppressive option with typical dosing of 10–15 mg once weekly. 2
For patients with normal renal function and no significant comorbidities, starting at 15 mg/week is reasonable; reserve a lower test dose of 2.5–5 mg for those with renal impairment, advanced age, or interacting medications. 3
Dose Escalation Protocol
Increase the dose by 5 mg every 2–4 weeks based on clinical response and tolerability, targeting 20–30 mg/week as the therapeutic range. 1
The FDA label for rheumatoid arthritis and psoriasis supports weekly doses up to 25 mg/week as standard maximum, with selected patients escalated to 30 mg/week under close supervision. 3, 4
Rapid escalation (5 mg/month to 25–30 mg/week) yields higher efficacy but increases gastrointestinal adverse events compared with slow escalation (5 mg every 3 months). 1
Clinical improvement in sarcoidosis may not be evident until 3–12 weeks after initiation or dose adjustment. 3
Route of Administration
Start with oral methotrexate; switch to subcutaneous or intramuscular administration if there is inadequate clinical response at the highest tolerable oral dose, gastrointestinal intolerance, or when doses exceed 20 mg/week due to bioavailability concerns. 1, 3
Parenteral methotrexate provides higher bioavailability and may reduce gastrointestinal toxicity, though it was associated with more withdrawal due to toxicity in early rheumatoid arthritis trials. 1
In sarcoidosis studies, patients receiving 15 mg/week showed significant improvement, with some evidence that higher cumulative doses correlate with better outcomes. 5
Folic Acid Supplementation
Prescribe at least 5 mg folic acid per week to reduce gastrointestinal and hepatic toxicity without compromising efficacy. 1
Administer folic acid daily on days other than the methotrexate dose day to avoid interfering with therapeutic effect. 3
Folic acid supplementation significantly reduces hepatotoxicity (OR 0.17; 95% CI 0.09–0.32) and gastrointestinal side effects. 1
Monitoring Requirements
Baseline Assessment
- Before starting methotrexate, obtain: CBC, AST/ALT, albumin, serum creatinine, chest radiograph (within the past year), and consider hepatitis B/C serology, HIV testing, fasting glucose, lipid profile, and pregnancy test. 1
During Therapy
Monitor CBC, liver enzymes (ALT ± AST), and creatinine every 1–1.5 months until a stable dose is achieved, then every 1–3 months thereafter. 1
Perform clinical assessment for side effects and risk factors at each visit. 1
For patients with psoriasis (similar monitoring applies to sarcoidosis), once stable, monitoring can be spaced to every 3–6 months. 3
Management of Hepatotoxicity
Stop methotrexate if ALT/AST rises >3× the upper limit of normal on confirmed repeat testing; the drug may be reinstituted at a lower dose after normalization. 1
If ALT/AST levels are persistently elevated up to 3× the upper limit of normal, adjust the methotrexate dose and consider diagnostic procedures. 1
Efficacy Data in Sarcoidosis
A 2025 randomized controlled trial demonstrated that methotrexate was noninferior to prednisone for first-line treatment of pulmonary sarcoidosis, with a mean FVC improvement of 6.11 percentage points (95% CI 3.72–8.50) at 24 weeks. 6
In chronic sarcoidosis, improvement in vital capacity or other affected organs was noted in 66% of patients (33 of 50) treated with methotrexate for at least 2 years. 7
A prospective study found that 55% of patients met response criteria (≥10% improvement in FEV1, FVC, TLC, or ≥15% improvement in DLCO) after methotrexate monotherapy. 5
Patients with lower baseline TLC and FVC values responded better to methotrexate treatment. 5
Methotrexate polyglutamate concentrations (MTXPG3 and MTXPG4) measured after 3 months of therapy showed significant negative correlation with FDG-PET SUVmax changes, suggesting a relationship between drug levels and anti-inflammatory effect. 8
Safety Profile
Methotrexate is appropriate for long-term use based on its acceptable safety profile in sarcoidosis. 1
In 150 patient-years of sarcoidosis treatment, major toxic effects included hepatic toxicity (6 patients requiring discontinuation), leukopenia requiring hospitalization (1 patient), and cough (1 patient). 7
In a prospective study, 22% of patients stopped treatment due to adverse events, with mild hepatic abnormalities in 20% and concomitant infection in 4%; there were no fatal outcomes. 5
The side-effect profile differs from prednisone: methotrexate causes nausea, fatigue, and liver function abnormalities, whereas prednisone causes weight gain, insomnia, and increased appetite. 6
Critical Safety Warnings
Methotrexate must be administered weekly, not daily; dosing errors are a major cause of life-threatening toxicity. 3
Discontinue methotrexate at least 3 months before planned pregnancy for both men and women; it is contraindicated during pregnancy and breastfeeding. 1
Avoid methotrexate in patients with significant renal failure, as it is cleared by the kidney. 2
Organ-Specific Considerations
For cardiac or neurologic sarcoidosis, practice patterns show that after corticosteroids, the second medication initiated on average was adalimumab for cardiac and mycophenolate for neurologic involvement, though methotrexate remains a guideline-endorsed option. 9
For cutaneous sarcoidosis, methotrexate at doses of 12.5–30 mg/week achieved complete remission in 75% of patients (3 of 4) after a mean treatment duration of 29 months. 10
In non-anterior sarcoidosis-associated uveitis, methotrexate demonstrated significantly longer time to treatment failure (median 34.5 months) compared with mycophenolate (8.4 months) and azathioprine (16.8 months). 11